<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01913652</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1202</org_study_id>
    <secondary_id>2012-003672-39</secondary_id>
    <secondary_id>cabazL06470</secondary_id>
    <nct_id>NCT01913652</nct_id>
  </id_info>
  <brief_title>Ph II Cabazitaxel DD Liposarcoma</brief_title>
  <official_title>Phase II Trial of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Soft tissue sarcomas (STS) are a rare group of malignant heterogenous tumors (&gt; 50
      histological subtypes, including liposarcoma, the commonest subtype of STS) with distinct
      genetic, pathological and clinical profiles, and varying patterns of tumor spread. The
      optimal cytotoxic treatment for this group of patients remains uncertain. Single agents which
      are most effective include doxorubicin and ifosfamide, but objective response rates and
      progression-free survival times remain modest. There is clearly a need to improve treatment
      options for liposarcoma. Eribulin, a antimicrotubule agent that targets the protein tubulin
      in cells, interfering with cancer cell division and growth , has demonstrated activity in
      STS. Therefore, it is reasonable to explore whether other anti-microtubule agent like
      cabazitaxel have a role in STS. Cabazitaxel has been shown to be a relatively safe, effective
      and tolerated. This drug has been approved by FDA for prostate cancer. The main objective of
      this trial is to determine whether cabazitaxel demonstrate sufficient antitumor activity for
      liposarcoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>3 years from first patient in</time_frame>
    <description>The primary endpoint will be progression free survival, assessed at 12 weeks after start of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>3 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>3 years from first patient in</time_frame>
    <description>Objective tumor response as defined by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of response</measure>
    <time_frame>3 years from first patient in</time_frame>
    <description>Time to onset of response will be measured for patients achieving an objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>3 years from first patient in</time_frame>
    <description>Duration of response will be measured for patients achieving an objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of adverse events</measure>
    <time_frame>3 years from first patient in</time_frame>
    <description>This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Dedifferentiated Liposarcoma</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INN: Cabazitaxel Cabazitaxel will be administered at a dose of 25 mg/m² by intravenous infusion, over 1 hour, on day 1 of each 21 day cycle.
Treatment should be administered until disease progression, unacceptable toxicity or patient's refusal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <other_name>Jevtana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Local diagnosis of dedifferentiated liposarcoma

          -  Age 18-75 yrs

          -  WHO performance status 0-1

          -  Radiological or histological diagnosis of inoperable locally advanced or metastatic
             disease, with evidence of disease progression within the past 6 months

          -  Clinically and/or radiographically documented measurable disease within 21 days prior
             to randomization.At least one site of disease must be unidimensionally measurable
             according to RECIST 1.1.

          -  One previous chemotherapy regimen for locally advanced or metastatic dedifferentiated
             liposarcoma (this could include pre-operative chemotherapy for primary disease if
             subsequent complete resection was not achieved).

          -  Adequate haematological, renal and hepatic function

          -  Birth control measures

          -  Estimated life expectancy &gt; 3 months

          -  Related adverse events from previous therapies ≤ Grade 1

          -  Written informed consent

        Exclusion Criteria:

          -  More than 1 prior molecularly targeted therapy (e.g. CDK4 inhibitor). Any prior such
             therapy must be completed at least 4 weeks before randomization.

          -  Symptomatic CNS metastases

          -  Previous encephalopathy of any cause or other significant neurological condition

          -  Concurrent or planned treatment with strong inhibitors or inducers of cytochrome P450
             3A4/5

          -  Pregnancy

          -  inflammation of the urinary bladder (cystitis)

          -  Other invasive malignancy within 5 years (exceptions of non-melanoma skin cancer,
             localized cervical cancer, localized and presumably cured prostate cancer or
             adequately treated basal or squamous cell skin carcinoma)

          -  Significant cardiac disease

          -  Uncontrolled severe illness or medical condition, other than DD liposarcoma

          -  Hypersensitivity to taxanes or their excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Hayward, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western General Hospital, Edinburgh, United Kingdom</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura De Meulemeester</last_name>
    <phone>+3227741568</phone>
    <email>laura.demeulemeester@eortc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ionela Stanciu</last_name>
    <phone>+32 2 774 1565</phone>
    <email>ionela.stanciu@eortc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen (117)</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Van Den Brande</last_name>
      <email>jan.van.den.brande@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet (101)</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Gil</last_name>
      <email>thierry.gil@bordet.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - Centre Georges-Francois-Leclerc (229)</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard (227)</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-yves Blay</last_name>
      <email>jean-yves.blay@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone (287)</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Duffaud</last_name>
      <email>florence.duffaud@mail.ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori (704)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Casali</last_name>
      <email>Paolo.Casali@istitutotumori.mi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS - Ospedale Busonera (3908)</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umberto Basso</last_name>
      <email>u.basso@tin.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology NHS Trust - Clatterbridge Cancer Centre NHS Foundation Trust (659)</name>
      <address>
        <city>Bebington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasim Ali</last_name>
      <email>nasim.ali@clatterbridgecc.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Ramage</last_name>
      <phone>0131 537 2916</phone>
      <email>paul.ramage@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Waddell</last_name>
      <phone>0131 537 2444</phone>
      <email>jennifer.waddell@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Larry Hayward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Chelsea, London (613)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Benson</last_name>
      <email>charlotte.benson@rmh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust (610)</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Leahy</last_name>
      <email>Michael.Leahy@christie.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2013</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dedifferentiated liposarcoma</keyword>
  <keyword>cabazitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

